Scholar Rock will present new Phase 3 SAPPHIRE trial data on apitegromab at the 2025 MDA conference, highlighting efficacy ...
Silver prices plunged late in the North American session, hitting a weekly low beneath $33.00, sustaining its most ...
To Novartis, fresh late-stage data support the idea that its intrathecal drug, which has the same active ingredient as ...
A pair of clinical data sets gives Novartis confidence in a new formulation of the company’s gene therapy Zolgensma for the ...
In the time since the Novartis gene therapy Zolgensma was approved for babies with spinal muscular atrophy, other treatments ...
Even though Silver hit a fresh five-day low of $33.10, it bounced off the latter and hovers in the mid $33-$34 range a troy ...
People in mostly middle-income survey countries say it’s ideal to start a family and own a home by 30, and retire by 60.
Zacks Investment Research on MSN3d
Novartis Reports Updated Positive Data From Phase III SMA ProgramNovartis NVS reported promising new safety and efficacy results from its phase III studies of investigational intrathecal ...
Clinical Trials Arena on MSN3d
Novartis reports Phase III efficacy and safety outcomes of SMA treatmentIn this trial, the efficacy and safety of the therapy were evaluated against a sham control in treatment-naïve SMA Type 2 ...
RADIO AIRPLAY AUDIENCE IMPRESSIONS AS PROVIDED BY LUMINATE AND SALES DATA AS COMPILED BY LUMINATE Neton Vega & Peso Pluma Last week Weeks at no. 1 Weeks on chart L.E.Vega Carvajal Neton Vega ...
The analysis focused on TrueView YouTube video advertisements. The three oldest age groups measured (age 45-54, age 55-64, and age 65+) have the average highest view rates for YouTube video ads, the ...
The SMA gene therapy candidate OAV101 IT, a version of Zolgensma, can be safely given to previously treated patients, per new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback